You need to be logged in to view this video

Unlocking the Pharmaceutical Potential of Cannabinoids

Released on Wednesday, July 14, 2021BIOTECH
With the recent acquisition of GWPH by Jazz Pharmaceuticals, many investors are wondering who might follow in their footsteps. Skye Bioscience (SKYE) has the right set-up—and advantages—to not just follow GW's leadership but carve a new path. SKYE is working to solve the world's leading cause of irreversible blindness by applying advanced science to uniquely unlock the therapeutic potential of cannabinoids and create important new pharmaceutical medicines. The lead program targets glaucoma, a disease with no cure and the world's leading cause of irreversible blindness. Preclinical data has demonstrated that SKYE's lead molecule, THCVHS, provides superior lowering of intraocular pressure, a key cause of vision loss, compared to the top commercially marketed classes of drugs that represent 80% of a nearly $7 billion market opportunity. With key value driving milestone and catalyst on the horizon SKYE is poised for significant growth.

Karam Takhar
Skye Bioscience, Inc., Vice President of Corporate Development and Investor Relations

Trending Now


Filter By Category
Filter By Keywords
Loading...
Live Now

Accredited Investors Virtual Expo

July 27 - 29, 2021